Characterization of Native Human Thrombopoietin in the Blood of Normal Individuals and of Patients with Haematologic Disorders

Summary

Thrombopoietin (TPO) isolated from thrombocytopenic plasma of various animal species has previously been shown to comprise only truncated forms of the molecule, presumably generated by proteolysis. Native TPO has now been partially purified from normal human plasma by immunoaffinity chromatography and was confirmed to be biologically active. Gel filtration in the presence of SDS revealed that TPO eluted in two peaks: a major peak corresponding to the elution position of fully glycosylated recombinant human TPO (rhTPO) consisting of 332 amino acid residues, and a minor peak corresponding to a smaller molecular size. Immunoblot analysis also revealed that most plasma-derived TPO migrated at the same position as fully glycosylated rhTPO, corresponding to a molecular size of ~80 to 100 kDa. Furthermore, the size distribution of circulating TPO in patients with various haematologic disorders did not differ markedly from that of plasma-derived TPO from healthy individuals. These results indicate that the truncation of circulating TPO is not related to disease pa-thophysiology, and that the predominant form of TPO in blood is a biologically active ~80- to 100-kDa species. The size distribution of TPO extracted from normal platelets was similar to that of TPO in plasma; the proportion of truncated TPO was decreased by prior incubation of platelets with hirudin, indicating that the endogenous truncated TPO, at least in platelet extract, was generated by thrombin-mediated cleavage.

• References

• 1 de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang W-J, Oles KJ, Hultgren B, Solberg LAJR, Goeddel DV, Eaton DL. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-8.
• 2 Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mathewes SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, O’Hara PJ, Hagen FS, Roth GJ, Foster DC. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-8.
• 3 Bartley TD, Bogenberger J, Hunt P, Li Y-S, Lu HS, Martin F, Chang M-S, Samal B, Nichol JL, Swift S, Johnson MJ, Hsu R-Y, Parker VP, Suggs S, Skrine JD, Merewether LA, Clogston C, Hsu E, Hokom MM, Hornkohl A, Choi E, Pangelinan M, Sun Y, Mar V, McNinch J, Simonet L, Jacobsen F, Xie C, Shutter J, Chute H, Basu R, Selander L, Trollinger D, Sieu L, Padilla D, Trail G, Elliot G, Izumi R, Covey T, Crouse J, Garcia A, Xu W, Del Castillo J, Biron J, Cole S, Hu MC-T, Pacifici R, Ponting I, Saris C, Wen D, Yung YP, Lin H, Bosselman RA. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117-24.
• 4 Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoiet In: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-8.
• 5 Kato T, Ogami K, Shimada Y, Iwamatsu A, Sohma Y, Akahori H, Horie K, Kokubo A, Kudo Y, Maeda E, Kobayashi K, Ohashi H, Ozawa T, Inoue H, Kawamura K, Miyazaki H. Purification and characterization of thrombopoietin. J Biochem (Tokyo) 1995; 118: 229-36.
• 6 Kato T. Protein characteristics of thrombopoietin. Stem Cells 1996; 14 (Suppl. 01) 139-47.
• 7 Folman CC, von dem Borne AGK, Rensink IJAM, Gerritsen W, van der Schoot CE, de Haas M, Aarden L. Sensitive measurement of thrombopoietin by a monoclonal antibody based sandwich enzyme-linked immunosorbent assay. Thromb Haemost 1997; 78: 1262-7.
• 8 Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantaion. Br J Haematol 1996; 95: 535-41.
• 9 Kato T, Oda A, Inagaki Y, Ohashi H, Matsumoto A, Ozaki K, Miyakawa Y, Watarai H, Fuju K, Kokubo A, Kadoya T, Ikeda Y, Miyazaki H. Thrombin cleaves recombinant human thrombopoiet In: one of the proteolytic events that generates truncated forms of thrombopoietin. Proc Natl Acad Sci USA 1997; 94: 4669-74.
• 10 Foster D, Lok S. Biological roles for the second domain of thrombopoietin. Stem Cells 1996; 14 (Suppl. 01) 102-7.
• 11 Shimada Y, Kato T, Ogami K, Horie K, Kokubo A, Kudo Y, Maeda E, Sohma Y, Akahori H, Kawamura K, Miyazaki H. Production of thrombopoietin (TPO) by rat hepatocytes and hepatoma cell lines. Exp Hematol 1995; 23: 1388-96.
• 12 Nomura S, Ogami K, Kawamura K, Tsukamoto I, Kudo Y, Kanakura Y, Kitamura Y, Miyazaki H, Kato T. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 1997; 25: 565-72.
• 13 McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668-75.
• 14 Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997; 89: 101-7.
• 15 Kaushansky K. Thrombopoiet In: the primary regulator of platelet production. Blood 1995; 86: 419-31.
• 16 Cohen-Solal K, Villeval J-L, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996; 88: 2578-84.
• 17 Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87: 567-73.
• 18 Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-30.
• 19 Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M, Ikeda Y. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995; 86: 23-7.
• 20 Miyakawa Y, Oda A, Druker BJ, Miyazaki H, Handa M, Ohashi H, Ikeda Y. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996; 87: 439-46.
• 21 Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller G, de Sauvage FJ, Eaton D. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89: 2782-8.
• 22 Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H, Matsumo-to A, Miyasaki H, Urabe A, Kato T. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 1996; 93: 783-8.
• 23 Morita H, Tahara T, Matsumoto A, Kato T, Miyazaki H, Ohashi H. Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Lett 1996; 395: 228-34.
• 24 Tahara T, Kuwaki T, Matsumoto A, Morita H, Watarai H, Inagaki Y, Ohashi H, Miyazaki H, Kato T. Neutralization of biological activity and inhibition of receptor binding by antibodies against human thrombopoie-tin. Stem Cells 1998; 16: 54-60.
• 25 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
• 26 Burnette WN. “Western blotting”: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981; 112: 195-203.
• 27 Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 1970; 19: 924-32.
• 28 Brown JE, Baugh RF, Hougie C. The inhibition of the intrinsic generation of activated factor X by heparin and hirudin. Thromb Res 1980; 17: 267-72.
• 29 Chang J-Y. The hirudin-binding site of human alpha-thrombin. Identification of lysyl residues which participate in the combining site of hiru-din-thrombin complex. J Biol Chem 1989; 264: 7141-6.
• 30 Sohma Y, Akahori H, Seki N, Hori T, Ogami K, Kato T, Shimada Y, Kawamura K, Miyazaki H. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994; 353: 57-61.
• 31 Kuter DJ, Miyazaki H, Kato T. The purification of thrombopoietin from thrombocytopenic plasma. In: Thrombopoiesis and Thrombopoietins. Molecular, Cellular, Preclinical, and Clinical Biology. Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D. eds Totowa, NJ; Humana Press: 1997: 143-64.
• 32 Linden H, Kaushansky K. The glycan domain of thrombopoietin enhances secretion. Blood 1997; 90 (suppl) 55a
• 33 Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J Cell Biol 1988; 106: 1659-65.
• 34 Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 1990; 110: 1361-7.
• 35 Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-52.
• 36 Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, March CJ, Kronheim SR, Druck T, Cannizzaro LA, Huebner K, Black RA. Molecular cloning of the interleukin-1β converting enzyme. Science 1992; 256: 97-100.